Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 1,757 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Major Depressive Disorders Clear all

Conditions: Psychotic Disorders, Depressive Disorder, Major, Depressive Disorder
Interventions: Mifepristone, Placebo Oral Tablet; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: Depression
Interventions: Parent Child Interaction Therapy-Emotion Development (PCIT-ED), Developmental Education Parenting Intervention (DEPI); Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 3 Years to 6 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: MAJOR DEPRESSIVE DISORDER
Interventions: INFLUENZA VACCINE, NaCl-saline placebo; Biological · Other
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Major Depressive Disorder, Bipolar Disorder, Schizophrenia
Interventions: Taking Action; Behavioral
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Depressive Disorder, Major
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Post-traumatic Stress Disorder, Major Depressive Disorder
Interventions: pregnenolone, placebo; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Major Depressive Disorder, MDD, Depression
Interventions: TC-5214, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 813 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 93
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 90 more

Conditions: Major Depressive Disorder (MDD)
Interventions: CTC-501; Drug
Lead sponsor: Chase Therapeutics Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Depressive Disorder, Major
Interventions: memantine, Placebo Oral Capsule; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Major Depressive Disorder With Suicidal Ideation With Intent
Interventions: MIJ821 Intravenous Injection, Placebo Intravenous Injection; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 6
States / cities: Birmingham, Alabama • Farmington, Connecticut • Oakland Park, Florida + 3 more

Conditions: Depressive Disorder, Major, Depression, Mood Disorders, Mental Disorder, Psychiatric Disorder
Interventions: transcranial magnetic stimulation; Procedure
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 22 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depression
Interventions: citalopram + tiodothyronine, or + pindolol, or + placebo; Drug
Lead sponsor: Mark Frye; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Major Depressive Disorder
Interventions: Tai-Chi-Chih (TCC), Health Education and Wellness Classes (HEW); Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 60 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Major Depressive Disorder
Interventions: Cytomel (liothyronine); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depression Disorder, Depression
Interventions: DMT-Medium Dose, DMT-Low Dose, THC-Medium Dose, THC-Low Dose; Drug
Lead sponsor: Deepak C. D'Souza; Other
Eligibility: 21 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Depressive Disorder, Major, Depressive Disorder, Minor, Dysthymic Disorder
Interventions: RESPECT-D, RESPECT-D-E (Enhanced); Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Keene, New Hampshire

Conditions: Major Depressive Disorder
Interventions: F2695 SR; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 828 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 68
States / cities: Dothan, Alabama • Scottsdale, Arizona • Beverly Hills, California + 57 more

Conditions: Major Depressive Disorder
Interventions: LY2216684, Placebo, SSRI; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 27
States / cities: Redlands, California • Sherman Oaks, California • Wildomar, California + 24 more

Conditions: Major Depressive Disorder
Interventions: NBI-1065845; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 49
States / cities: Huntsville, Alabama • Bryant, Arkansas • Little Rock, Arkansas + 42 more

Conditions: Depressive Disorder, Major
Interventions: Intranasal Placebo, Midazolam Placebo Solution, Midazolam, Esketamine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 9 Years to 17 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 18
States / cities: Hartford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 15 more

Conditions: Major Depression
Interventions: Conventional cognitive behavioral therapy, Religious cognitive behavioral therapy; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Glendale, California • Durham, North Carolina

Conditions: Posttraumatic Stress Disorder, Major Depressive Disorder, Transcranial Magnetic Stimulation, Repetitive
Interventions: Transcranial Magnetic Stimulation (TMS); Device
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Providence, Rhode Island

Conditions: Major Depressive Disorder
Interventions: Low Dose 5-hydroxytryptophan, High Dose 5-hydroxytryptophan, Low Dose Creatine Monohydrate, High Dose Creatine Monohydrate, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 65 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Depression, Major Depressive Disorder
Interventions: Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR); Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 9
States / cities: Little Rock, Arkansas • North Miami, Florida • Terre Haute, Indiana + 6 more

Search by objective public record fields.

Treatment of Schizoaffective Disorder Using Mifepristone

Effectiveness of Parent-Child Interaction and Emotion Development Therapy in Treating Preschool Children With Depression

Influenza Challenge in Mood Disorders

Taking Action for College Students

Effects of Tryptophan Depletion on Brain Processing of Emotions in Patients With Mood Disorders

Adjunctive Pregnenolone in Post-Traumatic Stress Disorder (PTSD) and Depression in Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans

A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

A Study in Patients With Major Depressive Disorder

Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression

Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent

Individualized Functional Connectivity Targeting in aiTBS for Depression

Can Additional Drug Therapy Accelerate Response Time to Antidepressants

Brain Connectivity and Response to Tai Chi in Geriatric Depression

Biochemical Brain Changes Correlated With The Antidepressant Effect Of Thyroid Hormones

Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans

Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial

Safety Study of F2695 SR in Major Depressive Disorder

A Study in Prevention of Re-emergence of Depression Symptoms

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

Cognitive Behavioral Treatments for Depression in Chronic Illness

rTMS for PTSD Comorbid With Major Depressive Disorder

5-HTP and Creatine for Depression R33 Phase

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder